110 related articles for article (PubMed ID: 14580244)
1. Should all adjuvant breast cancer patients receive a bisphosphonate?
Cameron DA
Breast Cancer Res; 2003; 5(6):296-9. PubMed ID: 14580244
[TBL] [Abstract][Full Text] [Related]
2. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients.
Saarto T; Vehmanen L; Virkkunen P; Blomqvist C
Acta Oncol; 2004; 43(7):650-6. PubMed ID: 15545185
[TBL] [Abstract][Full Text] [Related]
3. Should oral bisphosphonates be standard of care in women with early breast cancer?
Clemons M; Verma S
Breast Cancer Res Treat; 2005 Apr; 90(3):315-8. PubMed ID: 15830146
[TBL] [Abstract][Full Text] [Related]
4. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
5. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
[TBL] [Abstract][Full Text] [Related]
6. [Use of clodronate in the adjuvant treatment of breast cancer is questionable for the time being].
Elomaa I; Saarto T
Duodecim; 2001; 117(10):1021-2. PubMed ID: 12116460
[No Abstract] [Full Text] [Related]
7. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
Horváth Z
Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
[TBL] [Abstract][Full Text] [Related]
8. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant clodronate in breast cancer.
Paterson AH
Acta Oncol; 2005; 44(1):80-2; author reply 83-4. PubMed ID: 15848910
[No Abstract] [Full Text] [Related]
10. Adjuvant clodronate therapy in patients with locally advanced breast cancer--long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group.
Mardiak J; Bohunický L; Chovanec J; Sálek T; Koza I
Neoplasma; 2000; 47(3):177-80. PubMed ID: 11043842
[TBL] [Abstract][Full Text] [Related]
11. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
Powles T; Paterson S; Kanis JA; McCloskey E; Ashley S; Tidy A; Rosenqvist K; Smith I; Ottestad L; Legault S; Pajunen M; Nevantaus A; Männistö E; Suovuori A; Atula S; Nevalainen J; Pylkkänen L
J Clin Oncol; 2002 Aug; 20(15):3219-24. PubMed ID: 12149294
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Coleman RE
Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
[TBL] [Abstract][Full Text] [Related]
14. [Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
Bull Cancer; 1993; 80(10 Suppl):50-6. PubMed ID: 8081032
[No Abstract] [Full Text] [Related]
15. Oral bisphosphonates as adjuvant therapy for operable breast cancer.
Powles T; McCroskey E; Paterson A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6301s-6304s. PubMed ID: 17062718
[TBL] [Abstract][Full Text] [Related]
16. The role of bisphosphonates in early breast cancer.
Paterson AH
Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates as adjuvant treatment for breast cancer.
Gralow JR
BMJ; 2002 Nov; 325(7372):1051-2. PubMed ID: 12424151
[No Abstract] [Full Text] [Related]
18. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients.
Atula S; Powles T; Paterson A; McCloskey E; Nevalainen J; Kanis J
Drug Saf; 2003; 26(9):661-71. PubMed ID: 12814333
[TBL] [Abstract][Full Text] [Related]
19. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
20. [Expanding the possibilities of using biphosphonates for prophylaxis and treatment of osteal complications in malignant metastasis].
Svishchenko IuA; Shimanovskiĭ NL
Eksp Klin Farmakol; 2004; 67(6):66-71. PubMed ID: 15707020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
